Strong Amgen stock trades above $430 as Q2 2026 beat lifts guidance and valuation debate

Amgen stock is holding above $430 after Q2 2026 results delivered a clear earnings and revenue beat and higher full-year guidance, even as valuation models flag the shares as overvalued versus intrinsic value and average price targets.

Amgen Inc. (ISIN US0311621009) stock is holding at $432.42 in late August 2026 after a strong second-quarter earnings beat and higher full-year guidance pushed the biotech group to fresh highs and triggered a wave of valuation debate as investors weigh fundamentals against a richly priced share level as of August 31, 2026.

Per recent market data as of August 28, 2026, Amgen stock closed at $432.42 on its primary US listing, placing the shares above both the 50-day moving average of $388.64 and the 200-day moving average of $364.71, with the closing level implying a market capitalization of $233.78 billion at that date.

In its latest reported quarter, Amgen delivered second-quarter 2026 revenue of $10.05 billion, up 9.5 percent year over year, and adjusted earnings of $6.29 per share versus a consensus estimate of $5.62, while management raised full-year 2026 guidance to revenue of $38.2 billion-$39.4 billion and non-GAAP EPS of $22.30-$23.50, a set of figures that now frames the valuation conversation around the stock.

Q2 2026 earnings beat and guidance hike

For the three months to the second quarter of 2026, Amgen reported revenue of $10.05 billion, marking 9.5 percent year-on-year growth compared with the same period of 2025 and surpassing a market consensus figure near $9.42 billion, which underscores the company’s ability to grow its portfolio at a high single-digit to low double-digit pace while still beating expectations on the top line.

On the earnings side, adjusted EPS reached $6.29 in Q2 2026, above the $5.62 per share consensus, implying an earnings beat of $0.67 per share and reflecting robust operating leverage as the company scaled up sales across key biologic therapies and newer assets that have begun to contribute more strongly to profit.

Following these results, Amgen’s management team increased full-year 2026 revenue guidance to a range of $38.2 billion-$39.4 billion from a prior band of $37.0 billion-$38.4 billion, and lifted non-GAAP EPS guidance to $22.30-$23.50, giving investors a more confident outlook that earnings growth should continue beyond the second quarter and offering a concrete framework against which the current share price of $432.42 can be assessed.

Analyst targets and valuation signals versus the share price

The rally that followed Amgen’s Q2 2026 beat has pushed the stock close to record levels, with market data indicating the shares have advanced 55.6 percent over the past year and now trade at $432.42, just 3.3 percent below a recent 52-week high of $447.03 that was reached on August 25, 2026, highlighting how much of the earnings momentum has been capitalized into the price.

Average analyst price targets have not fully kept pace with the move: an overview of sell-side estimates shows a consensus target near $380.43, which is below the current market price of $432.42 by $51.99, indicating the stock is trading more than 13 percent above the average target and underscoring a cautious stance among analysts relative to the market’s enthusiasm.

Valuation models add further nuance, with one discounted cash flow analysis citing an intrinsic value of $295.98 per Amgen share versus the current price of $432.42, a gap of $136.44 that translates into a negative margin of safety of 46.1 percent and supports the thesis that, on a purely valuation-driven basis, the stock appears significantly overvalued even after taking into account the upgraded FY 2026 EPS guidance.

Another intrinsic value framework, the GF Value metric, pegs fair value for Amgen at $365.50 per share, while the prevailing market price of $432.42 sits 18.3 percent above that estimate, reinforcing the argument that investors are paying a premium for growth visibility, pipeline strength, and the quality of cash flows, and raising the bar for future quarters to justify the higher valuation.

Despite these valuation concerns, consensus EPS expectations for the current year remain aligned with Amgen’s raised guidance, with average sell-side forecasts pointing to full-year 2026 earnings of 22.97 per share, slightly above the top end of the company’s own non-GAAP guidance range, suggesting that analysts believe further upside is possible if operational execution and margin discipline remain strong.

Dividend, peer performance and risk-reward context

Beyond earnings, Amgen continues to emphasize shareholder returns through its dividend policy, with a quarterly payout of $2.52 per share that, annualized, equates to $10.08 per share, providing a cash income stream that complements the stock’s capital appreciation and supports demand among income-oriented investors even as valuation multiples stretch higher.

Looking across the general drug manufacturers segment, Amgen’s share price of $432.42 and its rise of 55.6 percent over the past year stand out compared with many large-cap peers that have delivered more modest gains, which suggests that the market is assigning a premium to Amgen’s specific growth profile, its biologics and specialty franchise, and its execution on integrating acquired assets into the portfolio.

At the same time, the stock’s position just 3.3 percent below its 52-week high of $447.03 and its trading level more than 13 percent above the average price target and 18.3 percent above the GF Value estimate underscore that the risk-reward balance is more finely poised, with valuation risk rising even as fundamentals remain solid and guidance is higher, making future quarters’ results and pipeline updates critical to sustaining the current share price.

Repatha as a flagship cardiovascular product

Within Amgen’s portfolio, the PCSK9 inhibitor Repatha has become a flagship product in the cardiovascular segment, and fresh clinical data released on August 31, 2026 indicate that Repatha can reduce the risk of death in patients at high risk for a first heart attack or stroke, expanding the therapy’s potential impact and supporting its role in long-term revenue growth.

The new findings focus on patients with elevated cardiovascular risk profiles who had not yet suffered a heart attack or stroke but were deemed at high risk of such events, and the data showed that Repatha treatment led to a statistically significant reduction in all-cause mortality compared with standard care, reinforcing the drug’s position as a key preventative therapy in lipid management.

For Amgen, stronger outcomes data for Repatha not only enhance the product’s clinical profile but also open the door to broader prescribing across primary prevention settings, which can translate into higher volumes over time and help support the company’s upgraded revenue guidance for 2026 and beyond, particularly as payers and providers look to therapies that can demonstrably lower event rates and mortality.

Closing view on Amgen stock and current price level

As of the close on August 28, 2026, Amgen stock traded at $432.42 on the Nasdaq, with the shares sitting above their 50-day and 200-day moving averages and just shy of the 52-week high of $447.03, a technical picture that reflects strong momentum but also an elevated valuation relative to intrinsic value models and average analyst price targets.

Company fact box

Company: Amgen Inc.

ISIN: US0311621009

Ticker: AMGN

Exchange: Nasdaq

Price (as of August 28, 2026, 4:00 p.m. ET): $432.42 USD

Market cap: $233.78 billion (as of August 28, 2026)

Sector / Industry: Health care / Biotechnology

Index membership: Dow Jones Industrial Average, S&P 500